DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactEarnings

Prime Focus Limited — Outcome of Board Meeting

NSE 1 hr ago·23 Sept 2026, 2:36 am

Prime Focus

Prime Focus Limited has informed the stock exchanges about the outcome of its board meeting held on September 23, 2026. The company has not disclosed specific details of the discussions in the public announcement, leaving investors to await further official information regarding the agenda items covered.

This announcement is significant for investors as it signals that the company is actively managing its strategic direction and governance. Since the specific business decisions remain undisclosed, the market will closely watch for any subsequent disclosures to understand the potential impact on the company's future operations and performance.

Investors should monitor the company's future filings for clarity on the board's decisions. Until the company provides more context, it is advisable to wait for additional information before drawing any conclusions about the implications for the stock.